A study in Clinical Cancer Research revealed that pancreatic cancer patients with diabetes who took metformin lived longer than those who did not take the drug. Researchers looked at 302 patients with both conditions and found that 30.1% of metformin-treated patients survived after two years, compared with 15.4% of those who did not receive metformin.

Full Story:

Related Summaries